TNFα: Activator or inhibitor of regulatory T cells?

Joint Bone Spine

Volumn 79, Issue 2, 2012, Pages 119-123

  Biton, Jérôme ^a   Boissier, Marie Christophe ^a,b   Bessis, Natacha ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

Rheumatoid arthritis; TNF antagonists; TNF regulatory T cells

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GALECTIN 1; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 35; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANTIINFLAMMATORY ACTIVITY; CD4+ CD25+ T LYMPHOCYTE; CELL EXPANSION; CELL MATURATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SHORT SURVEY; SYNOVIUM; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HUMANS; MICE; RHEUMATIC DISEASES; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857800767     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.09.017     Document Type: Short Survey

References (44)

1. Ehrenstein M.R., Evans J.G., Singh A., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF-alpha therapy. J Exp Med 2004, 200:277-285.
2. Lawson C.A., Brown A.K., Bejarano V., et al. Early rheumatoid arthritis is associated with a deficit in the CD4+ CD25high regulatory T cell population in peripheral blood. Rheumatology (Oxford) 2006, 45:1210-1217.
3. Chen X., Subleski J.J., Kopf H., et al. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+ CD25+ FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol 2008, 180:6467-6471.
4. Valencia X., Stephens G., Goldbach-Mansky R., et al. TNF downmodulates the function of human CD4+ CD25hi T regulatory cells. Blood 2006, 108:253-261.
5. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3:745-756.
6. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992, 10:411-452.
7. Sethi G., Sung B., Aggarwal B.B. TNF: a master switch for inflammation to cancer. Front Biosci 2008, 13:5094-5107.
8. Black R.A., Rauch C.T., Kozlosky C.J., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385:729-733.
9. Faustman D., Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov 2010, 9:482-493.
10. Sfikakis P.P. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010, 11:180-210.
11. Jacob C.O., McDevitt H.O. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 1988, 331:356-358.
12. Yang X.D., Tisch R., Singer S.M., et al. Effect of tumor necrosis factor-alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994, 180:995-1004.
13. Boissier M.C., Assier E., Biton J., et al. Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine 2009, 76:10-14.
14. Wildin R.S., Smyk-Pearson S., Filipovich A.H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002, 39:537-545.
15. Brunkow M.E., Jeffery E.W., Hjerrild K.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27:68-73.
16. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
17. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat Rev Immunol 2008, 8:523-532.
18. Chen X., Baumel M., Mannel D.N., et al. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+ CD25+ T regulatory cells. J Immunol 2007, 179:154-161.
19. Aspalter R.M., Eibl M.M., Wolf H.M. Regulation of TCR-mediated T cell activation by TNF-RII. J Leukoc Biol 2003, 74:572-582.
20. Chen X., Hamano R., Subleski J.J., et al. Expression of costimulatory TNFR2 induces resistance of CD4+ FoxP3- conventional T cells to suppression by CD4+ FoxP3+ regulatory T cells. J Immunol 2010, 185:174-182.
21. Zorn E., Nelson E.A., Mohseni M., et al. IL-2 regulates FOXP3 expression in human CD4+ CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006, 108:1571-1579.
22. Chen X., Subleski J.J., Hamano R., et al. Co-expression of TNFR2 and CD25 identifies more of the functional CD4+ FOXP3+ regulatory T cells in human peripheral blood. Eur J Immunol 2010, 40:1099-1106.
23. Guillot X., Semerano L., Saidenberg-Kermanac'h N., et al. Vitamin D and inflammation. Joint Bone Spine 2010, 77:552-557.
24. Kleijwegt F.S., Laban S., Duinkerken G., et al. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol 2010, 185:1412-1418.
25. Read S., Greenwald R., Izcue A., et al. Blockade of CTLA-4 on CD4+ CD25+ regulatory T cells abrogates their function in vivo. J Immunol 2006, 177:4376-4383.
26. Flores-Borja F., Jury E.C., Mauri C., et al. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci USA 2008, 105:19396-19401.
27. Miyara M., Yoshioka Y., Kitoh A., et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009, 30:899-911.
28. Nagar M., Jacob-Hirsch J., Vernitsky H., et al. TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function. J Immunol 2010, 184:3570-3581.
29. Hamano R., Huang J., Yoshimura T., et al. TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. Eur J Immunol 2011, 41:2010-2020.
30. Lewis M., Tartaglia L.A., Lee A., et al. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA 1991, 88:2830-2834.
31. Chen X., Oppenheim J.J. The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4(+) FoxP3(+) regulatory T cells. Immunology 2011, 133:426-433.
32. Axmann R., Bohm C., Kronke G., et al. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 2009, 60:2747-2756.
33. Probert L., Plows D., Kontogeorgos G., et al. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol 1995, 25:1794-1797.
34. Bessis N., Chiocchia G., Kollias G., et al. Modulation of proinflammatory cytokine production in tumour necrosis factor-alpha (TNF-alpha)-transgenic mice by treatment with cells engineered to secrete IL-4, IL-10 or IL-13. Clin Exp Immunol 1998, 111:391-396.
35. Biton J., Semerano L., Delavallee L., et al. Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis. J Immunol 2011, 186:3899-3910.
36. Grinberg-Bleyer Y., Saadoun D., Baeyens A., et al. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest 2010, 120:4558-4568.
37. Cao D., van Vollenhoven R., Klareskog L., et al. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004, 6:R335-R346.
38. Jiao Z., Wang W., Jia R., et al. Accumulation of FoxP3-expressing CD4+ CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis. Scand J Rheumatol 2007, 36:428-433.
39. Sempere-Ortells J.M., Perez-Garcia V., Marin-Alberca G., et al. Quantification and phenotype of regulatory T cells in rheumatoid arthritis according to disease activity score-28. Autoimmunity 2009, 42:636-645.
40. van Amelsfort J.M., Jacobs K.M., Bijlsma J.W., et al. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004, 50:2775-2785.
41. Liu M.F., Wang C.R., Fung L.L., et al. The presence of cytokine-suppressive CD4+ CD25+ T cells in the peripheral blood and synovial fluid of patients with rheumatoid arthritis. Scand J Immunol 2005, 62:312-317.
42. Nadkarni S., Mauri C., Ehrenstein M.R. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007, 204:33-39.
43. Housley W.J., Adams C.O., Nichols F.C., et al. Natural but not inducible regulatory T cells require TNF-{alpha} signaling for in vivo function. J Immunol 2011, 186:6779-6787.
44. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465. The Lenercept multiple sclerosis study group and the university of British Columbia MS/MRI analysis group.